Monoclonal Antibody to Neutrophil Gelatinase Associated Lipocalin (NGAL)
Code | Size | Price |
---|
MAB388Ra21-20ul | 20ul | £92.00 |
Quantity:
MAB388Ra21-100ul | 100ul | £173.00 |
Quantity:
MAB388Ra21-200ul | 200ul | £235.00 |
Quantity:
MAB388Ra21-1ml | 1ml | £542.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Clonality: Monoclonal
Regulatory Status: RUO
Target Species: Rat
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
Lipocalin-2; LCN2; p25; Lipocalin 2; Oncogene 24p3; 25 kDa alpha-2-microglobulin-related subunit of MMP-9; Siderocalin LCN2
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Neutrophil gelatinase-associated lipocalin
Potency (Clone Number):
D2
Source:
Monoclonal antibody preparation
Usage:
Western blotting: 0.5-2ug/mL;1:500-2000<br/>Immunohistochemistry: 5-20ug/mL;1:50-200<br/>Immunocytochemistry: 5-20ug/mL;1:50-200<br/>Optimal working dilutions must be determined by end user.
Related Products
Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Recombinant Neutrophil Gelatinase Associated Lipocalin (NGAL) | RPB388Ra01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||